PMID: 9165995Apr 1, 1997Paper

Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation

Annals of the Rheumatic Diseases
S ten WoldeB A Dijkmans

Abstract

To assess the effect of resumption of second line drugs in patients with rheumatoid arthritis (RA) that flared after treatment discontinuation. RA patients were studied whose RA flared up after discontinuation of second line treatment while being in remission and who received a second course of the drug. Disease activity parameters were prospectively assessed at the time of treatment discontinuation, during the period when the disease flared up, and three months thereafter. Furthermore the medical charts were reviewed at 12 months after treatment resumption. There were 51 patients included in the study: 25 patients treated with antimalarial drugs, 10 with parenteral gold, four with d-penicillamine, eight with sulphasalazine, two with azathioprine, and two with methotrexate. Disease activity parameters showed significant improvement within three months of treatment resumption, but remained significantly worse when compared with that measured before treatment discontinuation. Within three months 47% of the patients fulfilled 20% response criteria. Disease activity 12 months after treatment resumption was considered to be absent in 35%, mild in 43%, and moderate or active in 22% of the patients. In four (8%) patients the resumed t...Continue Reading

References

May 1, 1979·Arthritis and Rheumatism·W F Kean, T P Anastassiades
Apr 1, 1976·Southern Medical Journal·R CadeG Spooner
Sep 1, 1983·Arthritis and Rheumatism·A E Evers, W R Sundstrom
Apr 1, 1984·Annals of the Rheumatic Diseases·M J AhernP J Maddison
Dec 1, 1981·Annals of the Rheumatic Diseases·M De Silva, B L Hazleman
Oct 1, 1981·Arthritis and Rheumatism·R S PinalsR A Larsen

❮ Previous
Next ❯

Citations

Mar 24, 2011·Current Opinion in Rheumatology·Marianne van den BroekCornelia F Allaart
Mar 24, 2011·Current Opinion in Rheumatology·Josef S Smolen, Daniel Aletaha
Oct 8, 2004·Expert Opinion on Therapeutic Targets·Andrew D Cook, Kumar Visvanathan
Feb 6, 2010·Scandinavian Journal of Rheumatology·T Tiippana-KinnunenM Leirisalo-Repo
Apr 16, 2015·Annals of the Rheumatic Diseases·Ronald F van VollenhovenKarin Franck-Larsson
Mar 13, 2016·Autoimmunity Reviews·Christopher K Y ChanChristopher J Edwards
Jul 6, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Cécile Gaujoux-VialaUNKNOWN French Society for Rheumatology
Feb 18, 2015·Nature Reviews. Rheumatology·Josef S Smolen, Daniel Aletaha
May 31, 2003·Nature Reviews. Drug Discovery·Josef S Smolen, Günter Steiner
Feb 18, 2014·The Journal of Rheumatology·Margot J WalterJolanda J Luime
Jun 25, 2021·Journal of Inflammation Research·Lene Terslev, Mikkel Ostergaard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.